FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Steven Chrysant

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Steven G Chrysant
Treating blood pressure to prevent strokes: The age factor.
Steven G Chrysant; George S Chrysant
New insights into the true nature of the obesity paradox and the lower cardiovascular risk.
Steven G Chrysant; F Wilford Germino; Joel M Neutel
Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Steven Chrysant (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Steven G Chrysant
Treating blood pressure to prevent strokes: The age factor.
World journal of cardiology 2013;5(3):22-7.
2013: Steven G Chrysant; George S Chrysant
New insights into the true nature of the obesity paradox and the lower cardiovascular risk.
Journal of the American Society of Hypertension : JASH 2013;7(1):85-94.
2012: Steven G Chrysant; F Wilford Germino; Joel M Neutel
Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2012;12(6):375-89.
2012: Steven G Chrysant; George S Chrysant
The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension.
Journal of clinical hypertension (Greenwich, Conn.) 2012;14(9):644-9.
2012: Steven G Chrysant; Victor Fernandez; Joseph L Izzo; Dean J Kereiakes; James Lee; Thomas Littlejohn; Michael Melino; Suzanne Oparil; Reinilde Heyrman
Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2012;12(4):233-43.
2012: Steven G Chrysant
Blood pressure effects of high-dose amlodipine-benazepril combination in Black and White hypertensive patients not controlled on monotherapy.
Drugs in R&D 2012;12(2):57-64.
2012: Steven G Chrysant
The role of angiotensin II receptors in stroke protection.
Current hypertension reports 2012;14(3):202-8.
2012: Steven G Chrysant; George S Chrysant
Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors.
The American journal of cardiology 2012;109(11):1681-5.
2012: Steven G Chrysant; George S Chrysant
Current status of β-blockers for the treatment of hypertension: an update.
Drugs of today (Barcelona, Spain : 1998) 2012;48(5):353-66.
2012: Dean J Kereiakes; James Lee; Thomas Littlejohn; Michael Melino; Suzanne Oparil; Steven G Chrysant; Victor Fernandez; Joseph L Izzo; Reinilde Heyrman
Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension.
Journal of clinical hypertension (Greenwich, Conn.) 2012;14(3):149-57.
2012: Steven G Chrysant; Victor Fernandez; Joseph L Izzo; Dean J Kereiakes; James Lee; Thomas Littlejohn; Michael Melino; Suzanne Oparil; Reinilde Heyrman
Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study.
Journal of the American Society of Hypertension : JASH 2012;6(2):132-41.
2012: Dean J Kereiakes; James Lee; Thomas Littlejohn; Michael Melino; Steven G Chrysant; Victor Fernandez; Joseph L Izzo; Reinilde Heyrman
Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.
Cardiovascular diabetology 2012;11():134.
2011: Joseph L Izzo; Dean J Kereiakes; James Lee; Thomas Littlejohn Iii; Michael Melino; Suzanne Oparil; Steven G Chrysant; Victor Fernandez; Reinilde Heyrman
24-hour efficacy and safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy.
Journal of clinical hypertension (Greenwich, Conn.) 2011;13(12):873-80.
2011: Steven G Chrysant
Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension.
Postgraduate medicine 2011;123(6):21-31.
2011: Marc Rendell; Steven G Chrysant
Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Postgraduate medicine 2011;123(4):183-6.
2011: Steven G Chrysant; George S Chrysant
Current status of aggressive blood glucose and blood pressure control in diabetic hypertensive subjects.
The American journal of cardiology 2011;107(12):1856-61.
2011: Raymond Townsend; Neville Bittar; Jeffrey Rosen; William Smith; Andrea Ramsay; Steven G Chrysant; Robert Weiss; Aldina Pivodic; Brigitte Duquesroix; Jacques Djian
Blood pressure effects of naproxcinod in hypertensive patients.
Journal of clinical hypertension (Greenwich, Conn.) 2011;13(5):376-84.
2011: Steven G Chrysant
Current status of aggressive blood pressure control.
World journal of cardiology 2011;3(3):65-71.
2011: Steven G Chrysant
A new paradigm in the treatment of the cardiovascular disease continuum: focus on prevention.
Hippokratia 2011;15(1):7-11.
2010: Steven G Chrysant; Alexander V Murray; Uta C Hoppe; Dan Dattani; Samir Patel; Shannon Ritter; Jack Zhang
Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension.
Current medical research and opinion 2010;26(12):2841-9.
2010: Suzanne Oparil; Steven G Chrysant; M Melino; J Lee; S Karki; R Heyrman
Long-term efficacy of a combination of amlodipine and olmesartan medoxomil ± hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial.
Journal of human hypertension 2010;24(12):831-8.
2010: Steven G Chrysant; J Lee; M Melino; S Karki; R Heyrman
Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension.
Journal of human hypertension 2010;24(11):730-8.
2010: Steven G Chrysant; George S Chrysant
Effectiveness of lowering blood pressure to prevent stroke versus to prevent coronary events.
The American journal of cardiology 2010;106(6):825-9.
2010: Steven G Chrysant
Current evidence on the hemodynamic and blood pressure effects of isometric exercise in normotensive and hypertensive persons.
Journal of clinical hypertension (Greenwich, Conn.) 2010;12(9):721-6.
2010: Steven G Chrysant; George S Chrysant; Catherine Chrysant; Mohammad Shiraz
The treatment of cardiovascular disease continuum: focus on prevention and RAS blockade.
Current clinical pharmacology 2010;5(2):89-95.
2010: Steven G Chrysant
Stopping the cardiovascular disease continuum: Focus on prevention.
World journal of cardiology 2010;2(3):43-9.
2010: Steven G Chrysant
Current status of dual Renin Angiotensin aldosterone system blockade for the treatment of cardiovascular diseases.
The American journal of cardiology 2010;105(6):849-52.
2010: Steven G Chrysant
The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan.
Drugs of today (Barcelona, Spain : 1998) 2010;46(3):151-62.
2010: Steven G Chrysant
The role of Angiotensin receptor blocker and calcium channel blocker combination therapy in treating hypertension: focus on recent studies.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2010;10(5):315-20.
2010: Steven G Chrysant
Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study.
Clinical drug investigation 2010;30(7):473-82.
2009: Steven G Chrysant; Suzanne Oparil; Michael Melino; Sulekha Karki; James Lee; Reinilde Heyrman
Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension.
Journal of clinical hypertension (Greenwich, Conn.) 2009;11(9):475-82.
2009: Steven G Chrysant
Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension.
Expert review of cardiovascular therapy 2009;7(8):887-95.
2009: Steven G Chrysant; Joel M Neutel; Keith C Ferdinand
Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.
Journal of the National Medical Association 2009;101(4):300-7.
2009: Steven G Chrysant; Kathleen J Chavanu; Jianbo Xu
Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2009;9(4):241-51.
2008: Suzanne Oparil; Steven G Chrysant; Dean Kereiakes; Jianbo Xu; Kathleen J Chavanu; William Waverczak; Robert Dubiel
Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients.
Journal of clinical hypertension (Greenwich, Conn.) 2008;10(12):911-21.
2008: Steven G Chrysant
Proactive compared with passive adverse event recognition: calcium channel blocker-associated edema.
Journal of clinical hypertension (Greenwich, Conn.) 2008;10(9):716-22.
2008: Steven G Chrysant
Amlodipine/ARB fixed-dose combinations for the treatment of hypertension: focus on amlodipine/olmesartan combination.
Drugs of today (Barcelona, Spain : 1998) 2008;44(6):443-53.
2008: Steven G Chrysant; George S Chrysant; Billy Dimas
Current and future status of beta-blockers in the treatment of hypertension.
Clinical cardiology 2008;31(6):249-52.
2008: Steven G Chrysant; Michael Melino; Sulekha Karki; James Lee; Reinilde Heyrman
The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study.
Clinical therapeutics 2008;30(4):587-604.
2008: Steven G Chrysant; Alexander V Murray; Uta C Hoppe; Dan Dattani; Samir Patel; Huang Hsu; Jack Zhang
Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
Current medical research and opinion 2008;24(4):1039-47.
2008: Steven G Chrysant
Aliskiren-hydrochlorothiazide combination for the treatment of hypertension.
Expert review of cardiovascular therapy 2008;6(3):305-14.
2008: William B White; Debra Murwin; Steven G Chrysant; Stephen Koval; Giora Davidai; Robert Guthrie
Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial.
Blood pressure monitoring 2008;13(1):21-7.
2008: Steven G Chrysant
Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum.
Clinical therapeutics 2008;30 Pt 2():2181-90.
2008: Steven G Chrysant
Using fixed-dose combination therapies to achieve blood pressure goals.
Clinical drug investigation 2008;28(11):713-34.
2007: Steven G Chrysant; B Dimas; M Shiraz
Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update.
Journal of human hypertension 2007;21(9):699-708.
2007: Steven G Chrysant
The pathophysiologic role of the brain renin-angiotensin system in stroke protection: clinical implications.
Journal of clinical hypertension (Greenwich, Conn.) 2007;9(6):454-9.
2007: Steven G Chrysant; Daniel H Sugimoto; Martin Lefkowitz; Thomas Salko; Mahmudul Khan; Vipin Arora; Victor Shi
The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy.
Blood pressure. Supplement 2007;1():10-7.
2007: Alberto Villamil; Steven G Chrysant; David Calhoun; Bonnie Schober; Huang Hsu; Linda Matrisciano-Dimichino; Jack Zhang
Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
Journal of hypertension 2007;25(1):217-26.
2006: Steven G Chrysant; Mohammed Ibrahim
Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.
Journal of clinical hypertension (Greenwich, Conn.) 2006;8(7):493-9; quiz 500-1.
2006: Steven G Chrysant; Thomas C Marbury; Tonous N Silfani
Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate.
Blood pressure monitoring 2006;11(3):135-41.
2006: Steven G Chrysant
Clinical experience with the use of angiotensin receptor blockers in patients with cardiovascular, cerebrovascular and renal diseases.
Current clinical pharmacology 2006;1(2):139-46.
2006: Steven G Chrysant; George S Chrysant
The pleiotropic effects of angiotensin receptor blockers.
Journal of clinical hypertension (Greenwich, Conn.) 2006;8(4):261-8.
2005: Steven G Chrysant
Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence.
Journal of human hypertension 2005;19(12):923-31.
2005: Ralph M Vicari; Bernard R Chaitman; Deborah Keefe; William B Smith; Steven G Chrysant; Melvin J Tonkon; Neville Bittar; Robert J Weiss; Hugo Morales-Ballejo; Udho Thadani
Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial.
Journal of the American College of Cardiology 2005;46(10):1803-11.
2005: Joel M Neutel; Thomas W Littlejohn; Steven G Chrysant; Ashish Singh
Telmisartan/Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension.
Hypertension research : official journal of the Japanese Society of Hypertension 2005;28(7):555-63.
2005: Steven G Chrysant; George S Chrysant; A Desai
Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan.
Journal of human hypertension 2005;19(3):173-83.
2004: Steven G Chrysant
Stroke prevention with losartan in the context of other antihypertensive drugs.
Drugs of today (Barcelona, Spain : 1998) 2004;40(9):791-801.
2004: Steven G Chrysant; George S Chrysant
Clinical experience with angiotensin receptor blockers with particular reference to valsartan.
Journal of clinical hypertension (Greenwich, Conn.) 2004;6(8):445-51.
2004: Steven G Chrysant; George S Chrysant
Pharmacological and clinical profile of moexipril: a concise review.
Journal of clinical pharmacology 2004;44(8):827-36.
2004: Steven G Chrysant; George L Bakris
Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy.
American journal of hypertension 2004;17(7):590-6.
2004: Steven G Chrysant; George S Chrysant
Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide.
Expert opinion on pharmacotherapy 2004;5(3):657-67.
2004: Steven G Chrysant; Michael A Weber; Antonia C Wang; Donald J Hinman
Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide.
American journal of hypertension 2004;17(3):252-9.
2003: Steven G Chrysant
The ALLHAT study: results and clinical implications.
QJM : monthly journal of the Association of Physicians 2003;96(10):771-3.
2003: Steven G Chrysant; George S Chrysant
Pharmacological profile and clinical use of moexipril.
Expert review of cardiovascular therapy 2003;1(3):345-52.
2003: Steven G Chrysant
Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT).
Expert review of cardiovascular therapy 2003;1(3):335-43.
2003: George S Chrysant; Steven G Chrysant
Has the role of calcium channel blockers in treating hypertension finally been defined?
Current hypertension reports 2003;5(4):295-300.
2003: Steven G Chrysant; Thomas C Marbury; T D Robinson
Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension.
Journal of human hypertension 2003;17(6):425-32.
2001: Suzanne Oparil; D Williams; Steven G Chrysant; Thomas C Marbury; J Neutel
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.
Journal of clinical hypertension (Greenwich, Conn.) 2001;3(5):283-91, 318.
2000: Steven G Chrysant; Alan B Weder; DA McCarron; M Canossa-Terris; JD Cohen; P A Gunter; Bruce P Hamilton; AJ Lewin; RF Mennella; LW Kirkegaard; Matthew R Weir; MH Weinberger
Effects of isradipine or enalapril on blood pressure in salt-sensitive hypertensives during low and high dietary salt intake. MIST II Trial Investigators.
American journal of hypertension 2000;13(11):1180-8.
2000: Steven G Chrysant
Treatment of white coat hypertension.
Current hypertension reports 2000;2(4):412-7.
1998: Matthew R Weir; Steven G Chrysant; DA McCarron; M Canossa-Terris; JD Cohen; P A Gunter; AJ Lewin; RF Mennella; LW Kirkegaard; J H Hamilton; MH Weinberger; Alan B Weder
Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives.
Hypertension 1998;31(5):1088-96.
1998: Steven G Chrysant; M Stimpel
Antihypertensive effectiveness of a very low fixed-dose combination of moexipril and hydrochlorothiazide.
Journal of cardiovascular pharmacology 1998;31(3):384-90.
1998: Steven G Chrysant
Vascular remodeling: the role of angiotensin-converting enzyme inhibitors.
American heart journal 1998;135(2 Pt 2):S21-30.
1998: Haralambos Gavras; Steven G Chrysant; A L Niederman; Thomas C Marbury; R Goldstein; E Conradi
Evaluation of enalapril combined with diltiazem ER in patients with stage 3-4 essential hypertension.
Clinical and experimental hypertension (New York, N.Y. : 1993) 1998;20(1):41-52.
1997: Steven G Chrysant; Matthew R Weir; Alan B Weder; DA McCarron; M Canossa-Terris; JD Cohen; RF Mennella; LW Kirkegaard; AJ Lewin; MH Weinberger
There are no racial, age, sex, or weight differences in the effect of salt on blood pressure in salt-sensitive hypertensive patients.
Archives of internal medicine 1997;157(21):2489-94.
1997: Steven G Chrysant; H Gavras; A L Niederman; Thomas C Marbury; R Goldstein
Clinical utility of long-term enalapril/diltiazem ER in stage 3-4 essential hypertension. Long-term Use of Enalapril/Diltiazem ER in Stage 3-4 Hypertension Group.
Journal of clinical pharmacology 1997;37(9):810-5.
1997: Steven G Chrysant
Perindopril/hydrochlorothiazide dose combinations for the treatment of hypertension: a multicenter study.
Journal of clinical pharmacology 1997;37(1):47-52.
1996: Steven G Chrysant; M Stimpel
A comparison of the antihypertensive effectiveness of a combination of moexipril or sustained-release verapamil with low-dose hydrochlorothiazide.
Journal of clinical pharmacology 1996;36(8):701-6.
1996: Steven G Chrysant; T Fagan; R Glazer; A Kriegman
Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension.
Archives of family medicine 1996;5(1):17-24; discussion 25.
1995: Steven G Chrysant; A A Fox; M Stimpel
Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients.
American journal of hypertension 1995;8(4 Pt 1):418-21.
1995: Steven G Chrysant; M Cohen
Sustained blood pressure control with controlled-release isradipine (isradipine-CR).
Journal of clinical pharmacology 1995;35(3):239-43.
1995: Steven G Chrysant; M Cohen
Sustained blood pressure control with controlled-release isradipine.
American journal of hypertension 1995;8(1):87-9.
1994: Steven G Chrysant; E Miller
Effects of atenolol and diltiazem-SR on exercise and pressure load in hypertensive patients.
Clinical cardiology 1994;17(12):670-4.
1994: Matthew R Weir; T Fagan; Steven G Chrysant; W Flamenbaum; P M Kaihlanen; M Lueg; D Anzalone
Comparison of the efficacy and tolerability of an angiotensin converting enzyme inhibitor (lisinopril) versus a calcium channel antagonist (diltiazem SR) in the treatment of moderate to severe hypertension.
Journal of human hypertension 1994;8(7):531-7.
1994: Steven G Chrysant
Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. A large multicenter study. Lisinopril-Hydrochlorothiazide Group.
Archives of internal medicine 1994;154(7):737-43.
1994: Steven G Chrysant; N Bittar
Betaxolol in the treatment of stable angina pectoris.
Cardiology 1994;84(4-5):316-21.
1993: Steven G Chrysant; Stephen P Glasser; N Bittar; F E Shahidi; K Danisa; R Ibrahim; L E Watts; R J Garutti; R Ferraresi; R Casareto
Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris.
The American journal of cardiology 1993;72(17):1249-56.
1993: Steven G Chrysant; R H McDonald; J T Wright; P L Barden; R J Weiss
Perindopril as monotherapy in hypertension: a multicenter comparison of two dosing regimens. The Perindopril Study Group.
Clinical pharmacology and therapeutics 1993;53(4):479-84.
1992: Steven G Chrysant; C Chappel; D J Farnham; B Levin; M Lueg; D McCluskey; C Steiner
Antihypertensive and metabolic effects of single and combined atenolol regimens.
Journal of clinical pharmacology 1992;32(1):61-5.
1991: Steven G Chrysant; C Chrysant; M Sadeghi; L Berlin
Cardiac changes from beta-blocker, diuretic and minoxidil combination in hypertension.
Cardiology 1991;78(1):45-52.
1989: Steven G Chrysant; C Chrysant; I S Bal; J Trus; A Hitchcock
Treatment of severe hypertension with atenolol and betaxolol with once-daily regimens. Hemodynamic aspects.
Chest 1989;96(3):499-504.
1989: Steven G Chrysant; C Chrysant; J Trus; A Hitchcock
Antihypertensive effectiveness of amlodipine in combination with hydrochlorothiazide.
American journal of hypertension 1989;2(7):537-41.
1988: Steven G Chrysant; C Chrysant; J Trus; A Hitchcock
Monotherapy of hypertension with darodipine: a new calcium-channel blocker.
Clinical cardiology 1988;11(7):467-72.
1988: Steven G Chrysant; L Ganousis; C Chrysant
Hemodynamic and metabolic effects of hypomagnesemia in spontaneously hypertensive rats.
Cardiology 1988;75(2):81-9.
1985: Steven G Chrysant; S Gollub; M I Dunn; I S Bal; R Dreiling; J R Konijeti
Hemodynamic and metabolic effects of enalapril in patients with heart failure.
Clinical cardiology 1985;8(11):585-90.
1985: Steven G Chrysant; I S Bal; B Johnson; M A McPherson
Antihypertensive effectiveness of terazosin: a new long-acting alpha-adrenergic inhibitor.
Clinical cardiology 1985;8(9):486-9.
1985: Steven G Chrysant; I S Bal; B Johnson; M McPherson
A comparative study of captopril and enalapril in patients with severe hypertension.
Journal of clinical pharmacology 1985;25(2):149-51.
1983: D F Lyons; W F Streck; D C Kem; R D Brown; D C Galloway; G R Williams; Steven G Chrysant; K Danisa; M Carollo
Captopril stimulation of differential renins in renovascular hypertension.
Hypertension 1983;5(4):615-22.
1983: Steven G Chrysant; R D Brown; D C Kem; J L Brown
Antihypertensive and metabolic effects of a new converting enzyme inhibitor, enalapril.
Clinical pharmacology and therapeutics 1983;33(6):741-6.
1981: Steven G Chrysant; R F Miller; J L Brown; K Danisa
Long-term hemodynamic and metabolic effects of trimazosin in essential hypertension.
Clinical pharmacology and therapeutics 1981;30(5):600-4.
1980: Steven G Chrysant; T M Luu
Effects of amiloride on arterial pressure and renal function.
Journal of clinical pharmacology 1980;20(5-6 Pt 1):332-7.
1980: Steven G Chrysant; T M Luu; K Danisa; D C Kem; C V Manion
Systemic and renal hemodynamic effects of trimazosin: a new vasodilator.
Journal of cardiovascular pharmacology 1980;2(2):205-14.